The FDA has accepted a priority review sNDA for Welireg in adults and pediatric patients with advanced or metastatic pheochromocytoma and paraganglioma. The U.S. Food and Drug Administration (FDA) has ...
The FDA granted priority review for belzutifan for treating advanced pheochromocytoma and paraganglioma, with a PDUFA date set for May 26, 2025. The FDA granted priority review to a supplemental new ...
Clinicians discuss the rapidly evolving therapies, technology, and surgical approaches for early-stage NSCLC and take a fresh look at the future of care. Teamwork: A Multidisciplinary Approach to ...
†High patient compliance after training. ‡Likely to be preferred for frail patients. Adapted from [34].
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback